SLC6A1-Related Disorder — Comprehensive Research Report

Prepared: 2026-07-25 · Target entity: SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD); GAT-1 GABA transporter epilepsy; epilepsy with myoclonic-atonic seizures (MAE/Doose-type) · Suggested MONDO: MONDO:0014633

Curation caveat up front (scope mismatch). MONDO:0014633 is labeled "epilepsy with myoclonic atonic seizures" and is defined against OMIM:616421 / ORPHA:1942 (Doose syndrome). That is a seizure-syndrome concept, whereas the modern clinical entity is a gene-defined neurodevelopmental disorder in which MAE is only one of several presentations (absence epilepsy, generalized epilepsy NOS, focal epilepsy, ID/ASD without epilepsy). Verified from OLS: MONDO:0014633 → label "epilepsy with myoclonic atonic seizures"; xrefs OMIM:616421, Orphanet:1942, DOID:0060475, MEDGEN:98284, UMLS:C0393702, SCTID:230421008, GARD:0016108, ICD9:345.10. A dedicated MONDO class for "SLC6A1-related neurodevelopmental disorder" does not currently exist (OLS search over MONDO for "SLC6A1" returns only MONDO:0014633). This repo already carries kb/disorders/Epilepsy_with_Myoclonic_Atonic_Seizures.yaml, so a new SLC6A1 entry should either (a) be curated as the gene-defined disorder with an explicit note that MONDO under-covers it, or (b) be modeled as a distinct entry with a differentials/mappings link to the MAE entry. Flag as an open ontology gap.

1. Disease Information

Overview

SLC6A1-related neurodevelopmental disorder is an autosomal dominant, de-novo-predominant condition caused by heterozygous loss-of-function variants in SLC6A1, which encodes GAT-1, the principal presynaptic and astrocytic GABA reuptake transporter of the CNS. The core clinical triad is developmental delay/intellectual disability with disproportionate language impairment, generalized epilepsy (most characteristically myoclonic-atonic and absence seizures, onset ~1.5–5 years), and behavioral/autistic features, frequently with hypotonia and a movement disorder (ataxia, tremor, stereotypies).

The mechanistic headline is counter-intuitive and worth encoding explicitly in the pathograph: losing a transporter for the brain's main inhibitory neurotransmitter causes epilepsy not by removing inhibition, but by letting ambient GABA linger and over-drive extrasynaptic, tonically active GABA-A receptors in thalamocortical circuits. Think of a sink whose drain is half-blocked — the problem is not too little water in the pipes, it's a basin that never empties, and downstream rhythm generation drowns in it.

Framing from the 2026 scoping review (PMID:42173049):

"Pathogenic heterozygous loss-of-function variants of SLC6A1 cause a developmental and epileptic encephalopathy characterized by early-onset epilepsy, intellectual disability, and autistic features."

Original gene-disease discovery (PMID:25865495, Am J Hum Genet 2015):

"GAT-1, encoded by SLC6A1, is one of the major gamma-aminobutyric acid (GABA) transporters in the brain and is responsible for re-uptake of GABA from the synapse. In this study, targeted resequencing of 644 individuals with epileptic encephalopathies led to the identification of six SLC6A1 mutations in seven individuals, all of whom have epilepsy with myoclonic-atonic seizures (MAE)."

Key identifiers

Synonyms / alternative names

SLC6A1-NDD · SLC6A1-related neurodevelopmental disorder · SLC6A1 deficiency disorder · SLC6A1 epileptic encephalopathy · GAT-1 deficiency · SLC6A1-related epilepsy · myoclonic-atonic epilepsy (MAE/EMAtS) · myoclonic-astatic epilepsy · Doose syndrome (when the seizure syndrome is the framing). MONDO synonym list for MONDO:0014633: "Doose syndrome", "EMAS", "EMAtS", "MAE", "myoclonic astatic epilepsy", "epilepsy with myoclonic-astatic seizures", "myoclonic-astatic epilepsy in early childhood".

Nature of the evidence base

Predominantly aggregated, provider-ascertained cohorts (Johannesen n=34; Goodspeed n=116; Kahen n=28; Brain 2023 n=172 with functional data on 184 variants; AJHG 2024 functional data on 213 variants) plus participatory/parent-report registries (Simons Searchlight NCT01238250, GenIDA). Individual-patient EHR data has been used once for healthcare-resource-utilization work (PMID:40624551, n=30 SLC6A1). Parent-report registry data has been formally benchmarked against provider publications and found broadly consistent (PMID:35761184). No prospective natural history results are yet published — a UCB-sponsored longitudinal natural history study (NCT07531511) started 2026-07-21.

2. Etiology

Primary causal factor

Monogenic. Heterozygous loss-of-function variants in SLC6A1, overwhelmingly de novo, causing reduced GAT-1-mediated GABA reuptake. Haploinsufficiency is the established mechanism (PMID:38781976):

"De novo variants consistently resulted in a decrease in GABA uptake, in keeping with haploinsufficiency underlying all neurodevelopmental phenotypes."

Contiguous-gene 3p25.3 microdeletions removing SLC6A1 together with SLC6A11 (GAT-3) are a second causal route (PMID:25256099, PMID:39923323, PMID:40517887). Balanced translocations disrupting SLC6A1 have also been reported (PMID:36966012; PMID:29621621, disrupting SLC6A1 and NAA15).

Genetic risk factors

• Causal: de novo missense (majority) and truncating variants; recurrent hotspots p.Gly232Val, p.Ala288Val, p.Val342Met, p.Gly362Arg (PMID:29315614).
• Constraint (gnomAD v4, retrieved via API): pLI ≈ 1.0; LoF observed/expected = 4/72.1 = 0.055, LOEUF (o/e upper bound) = 0.127; missense Z = 5.92; LoF Z = 6.81. Both LoF- and missense-constrained — consistent with observed missense enrichment in patients.
• Missense vulnerability + CpG hypermutability explain the clinical picture of recurrent de novo missense (PMID:38781976): "The extent of this missense vulnerability accounts for the clinically observed missense enrichment; overlap with hypermutable CpG sites accounts for the recurrent missense variants."
• Susceptibility (non-Mendelian) associations — treat as separate, weaker claims: rare damaging de novo missense in SLC6A1 is enriched in schizophrenia trios (PMID:31932766); SLC6A1 has been implicated in ADHD susceptibility with a reported gene-environment interaction (PMID:28442423) and in alcohol-use-disorder risk alongside GABBR1 (PMID:26727527); a 21-bp promoter insertion polymorphism creates an enhancer element and potentiates promoter activity (PMID:19077666).

Environmental risk factors

No established environmental cause. Advanced paternal age is the generic de-novo-mutation risk factor for this class of disorder but has not been specifically quantified for SLC6A1. No toxin, infection, or occupational exposure is implicated in disease causation.

Seizure/regression triggers (not causes) are documented: developmental regression episodes were "triggered by seizures, infection, or spontaneously" (PMID:36895422), and hyperventilation exacerbates the spike-wave EEG signature (GeneReviews).

Protective factors

None genetically established. No protective allele, modifier, or dietary exposure has been reported. Practically, the closest analogue to a "protective factor" is residual GAT-1 activity: variants retaining >10% GABA uptake are enriched in milder phenotypes (PMID:37647852).

Gene–environment interactions

Little formal data. The one specific report is a SLC6A1 × environment interaction in ADHD susceptibility (PMID:28442423) — this concerns common-variant susceptibility, not the Mendelian disorder, and should not be conflated in the KB entry. For the Mendelian disorder, the clinically meaningful "environment" is pharmacological: drugs that further reduce GAT-1 function (tiagabine) or that raise GABA tone would be expected to worsen the tonic-inhibition mechanism; levetiracetam is associated with disproportionate behavioral intolerance (GeneReviews).

3. Phenotypes

Frequency table (with sources and suggested HP terms — all HP IDs verified non-obsolete via OLS)

Phenotype characteristics

Age of onset. Cognitive/language concerns typically precede epilepsy. Scoping review (PMID:42173049): "seizure onset typically between 14 months and 5 years… cognitive impairment antedating seizure onset in over 60% of cases." Johannesen: "Epilepsy was diagnosed in 31/34 cases with mean onset at 3.7 years." Motor milestones are relatively spared: sitting ~9 mo (5–13), walking ~19 mo (11–33); language lags harder — babbling ~14 mo (6–36), first words ~25 mo (10–52), phrases ~34 mo (23–54) (GeneReviews).

Severity. Highly variable, mild to severe, and correlated with residual GAT-1 function (PMID:37647852): "For variants with complete loss of in vitro GABA uptake, we found a 4.6-fold enrichment in patients having severe disease versus non-severe disease (P = 2.9 × 10-3, 95% confidence interval: 1.5-15.3)."

Progression / course. Chronic and lifelong; epilepsy is often but not always treatable. Cognitive trajectory can worsen: "After epilepsy onset, cognition deteriorated in 46% (11/24) of cases" (PMID:29315614) and "Three out of five patients underwent at least two neuropsychological evaluations, which revealed a worsening of cognitive functions over time" (PMID:37700749). Regression: "The mean age at regression was 2.7 years and most subjects had regression of language or motor skills triggered by seizures, infection, or spontaneously" (PMID:36895422).

Adult phenotype (PMID:37662110, n=15 adults): "9/13 patients had moderate to severe ID… Epilepsy was prevalent (11/15)… Epilepsy was refractory in 7/11, while four patients were seizure free with lamotrigine, valproate, or lamotrigine in combination with valproate… Schizophrenia was not reported in any of the patients." Authors note ID "appeared to be more severe in the adult patients," with ascertainment bias as an alternative explanation.

Quality-of-life impact

First disease-specific QoL data (PMID:38663152, n=52 across a trial-readiness cohort and Simons Searchlight): mean QI-Disability 73 ± 12.3, QOLCE-55 49 ± 17.1, PedsQL Family Impact Module 51 ± 17.6; proposed clinically significant thresholds QI-Disability <61, QOLCE-55 <46, PedsQL-FIM <42. A longitudinal subset (n=7) showed a decline in the Family Relationship domain (Δ −10.0, P = 0.035).

Per-phenotype QoL drivers (PMID:41066795): "Lower QOLCE-55 total scores were associated with regression, absence seizures, clinical severity, coordination difficulties, and male gender (P < 0.039). Autism severity was significantly associated with lower total scores on all three QoL measures (P < 0.025; ρ = -0.473 to -0.681)." Autism severity — not seizure burden — is the single most consistent QoL driver across instruments. This is a curation-relevant, non-obvious finding.

4. Genetic / Molecular Information

Causal gene

SLC6A1 (hgnc:11042; NCBI Gene 6529; OMIM 137165), 3p25.3, encoding GAT-1 (UniProt P30531), a 599-aa, 12-TM sodium- and chloride-dependent neurotransmitter transporter of the SLC6/NSS (LeuT-fold) family.

UniProt function annotation: "Mediates transport of gamma-aminobutyric acid (GABA) together with sodium and chloride and is responsible for the reuptake of GABA from the synapse (PubMed:30132828)." Subcellular location: cell membrane; presynapse. Reverse (efflux) transport is thermodynamically possible depending on membrane potential and ion gradients — relevant to mechanism modeling.

Pathogenic variants

• Spectrum: missense (majority), nonsense, frameshift, splice-site, small intragenic indels; whole-gene deletion is rare. GeneReviews: "Sequence analysis detects >99% of pathogenic variants"; gene-targeted del/dup <1%.
• Missense:truncating ratio: 15/21 (71%) missense vs 6/21 (29%) truncating in the Simons Searchlight cohort (PMID:34006619).
• Structural clustering: "The GAT1 transmembrane domains 1, 6 and extracellular loop 4 (EL4) were enriched for patient over population variants" (PMID:37647852). Kahen: "Missense variants were largely clustered around the sixth and seventh transmembrane domains, which functions as a GABA binding pocket" (PMID:34006619). Ligand proximity predicts loss of function: "the spatial proximity from the ligand was associated with loss-of-function in the GAT1 transporter activity."
• ClinVar: 1,097 SLC6A1 records (NCBI eSearch, 2026-07-25). A large fraction remain unscored — AJHG 2024 notes "the functional data can inform future reports for the remaining 72% of unscored variants."
• Population allele frequency: pathogenic variants are essentially absent from gnomAD (4 observed LoF vs 72 expected across the gene); there is no common risk allele for the Mendelian disorder.
• Somatic vs germline: germline. Somatic/gonadal mosaicism is documented — a two-sibling pedigree with p.Val125Met absent in the asymptomatic mother, "suggesting gonadal mosaicism" (PMID:33961861).
• Functional consequence: loss of function → haploinsufficiency. Notably, dominant-negative and gain-of-function effects were specifically sought and not found at scale: "recurrent de novo missense variants showed moderate loss-of-function effects that reduced GABA uptake with no evidence for dominant-negative or gain-of-function effects" (PMID:38781976). This directly qualifies an earlier in-vitro observation that mutant GAT-1 can retain wild-type GAT-1 in the ER via aberrant oligomerization (PMID:35911425). Curate as competing hypotheses (mechanistic_hypotheses with hypothesis_groups), not as a settled dominant-negative claim.
• Two functional sub-classes of LoF missense (PMID:38781976): "two-thirds of loss-of-function missense variants prevented GAT-1 from being present on the membrane while GAT-1 was on the surface but with reduced activity for the remaining third." This distinction is therapeutically load-bearing — chaperone therapy targets the trafficking-defective two-thirds.
• Splicing: a splice-site variant "disrupted canonical splicing of exon 9 in the mRNA transcript, leading to premature protein truncation" (PMID:30132828).

Modifier genes

None established. Intrafamilial variability is documented (PMID:37502687 and its corrigendum PMID:37638311; PMID:33961861), and a hypomorphic allele (p.Ala334S) has been used to explain part of the variable expressivity (PMID:41174879): "We conclude that the p.A334S variant is a hypomorphic allele and begin to elucidate the underlying variability in SLC6A1-NDD." Allelic severity, not trans-acting modifiers, is the current best explanation.

Epigenetics

Not implicated in the Mendelian disorder. Separate literature: reduced DNA methylation around the SLC6A1 promoter in temporal lobe epilepsy (PMID:39344240) — an acquired-epilepsy finding, do not import into the Mendelian entry. A 21-bp promoter insertion polymorphism creating an enhancer element is a cis-regulatory variant of unclear clinical relevance (PMID:19077666).

Chromosomal abnormalities

• 3p25.3 microdeletion encompassing SLC6A1 + SLC6A11: "three novel patients with overlapping proximal microdeletions 3p25.3 of 1.1-1.5 Mb in size showing a consistent non-3p- phenotype with ID, epilepsy/EEG abnormalities, poor speech, ataxia and stereotypic hand movements" (PMID:25256099). Functionally confirmed: "The haploinsufficient GAT-1 and GAT-3 conditions demonstrated reduced GABA uptake and protein expression, comparable to known SLC6A1 missense variants" (PMID:39923323). Also PMID:40517887 (seizures/EEG in 3p deletion involving SLC6A1).
• Balanced translocations disrupting the locus (PMID:36966012; PMID:29621621).

5. Environmental Information

• Environmental factors: none causal. Not applicable.
• Lifestyle factors: none causal. Diet is relevant therapeutically (ketogenic diet, low glycemic index therapy) rather than etiologically.
• Infectious agents: none causal. Intercurrent infection is a documented trigger of developmental regression episodes (PMID:36895422) and, as in any epilepsy, of seizure exacerbation.
• Iatrogenic/pharmacological environment (the practically important one): tiagabine is a direct GAT-1 inhibitor (PMID:35676483) and the Slc6a1 knockout mouse "partially phenocopy[s] the clinical side effects of tiagabine" (PMID:15788781) — mechanistically, GAT-1 inhibitors should be avoided. Levetiracetam is associated with disproportionate behavioral intolerance (GeneReviews). Betaine, an endogenous osmolyte and dietary constituent, is a GAT-1 modulator (PMID:38884791) — a plausible but unproven dietary modifier.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream)

Node 1 — Molecular lesion (MOLECULAR). Heterozygous LoF variant in SLC6A1. For the trafficking-defective majority: mutant GAT-1 misfolds, is retained in the endoplasmic reticulum, and is degraded. PMID:34028503: "The reduced GABA uptake appears to be due to reduced cell surface expression of the variant transporter caused by variant protein misfolding, endoplasmic reticulum retention, and subsequent degradation." Reviewed in PMID:39268250: "many SLC6A1 mutations are now known to impair protein folding, and consequently fail to reach the plasma membrane." GO: GO:0005783 endoplasmic reticulum; GO:0006457 protein folding; GO:0030433 ubiquitin-dependent ERAD pathway; GO:0034976 response to ER stress.

Node 2 — Reduced cell-surface GAT-1 and reduced GABA uptake (MOLECULAR). Confirmed across 213 variants by ³H-GABA uptake (PMID:38781976) and in patient iPSC-derived astrocytes and neurons (PMID:34028503). In knock-in mice, "γ-aminobutyric acid transporter 1 protein was markedly reduced in cortex, hippocampus, thalamus and cerebellum in both mutant mouse lines" with no compensatory GAT-3 upregulation (PMID:38650830). GO: GO:0015812 gamma-aminobutyric acid transport; GO:0005332 GABA:sodium symporter activity; GO:0005886 plasma membrane; GO:0098793 presynapse. Modifier: DECREASED.

Node 3 — Elevated ambient/extracellular GABA and slowed synaptic GABA clearance (CELLULAR). PMID:35840120: "Reduced GABA uptake is due to decreased functional GAT-1, which, in thalamic astrocytes, could result in increased extracellular GABA accumulation and enhanced tonic inhibition, leading to seizures and abnormal EEGs." In KO mice, "The reduced rate of GABA clearance from the synaptic cleft is probably responsible for the slower decay of spontaneous IPSCs in cerebellar granule cells" (PMID:15788781). CHEBI: CHEBI:16865 gamma-aminobutyric acid (INCREASED, extracellular).

Node 4 — Increased extrasynaptic (δ-subunit) GABA-A receptor tonic conductance (CELLULAR). PMID:15788781: "The compromised GABA uptake in mGAT1 KO mice results in an increased GABA(A) receptor-mediated tonic conductance in both cerebellar granule and Purkinje cells." Generalized to absence epilepsy by PMID:19966779: "extrasynaptic GABA(A) receptor-dependent 'tonic' inhibition is increased in thalamocortical neurons from diverse genetic and pharmacological models of absence seizures. Increased tonic inhibition is due to compromised GABA uptake by the GABA transporter GAT-1 in the genetic models tested, and GAT-1 is crucial in governing seizure genesis." GO: GO:1902476 chloride transmembrane transport; GO:0060080 inhibitory postsynaptic potential.

Node 5 — Thalamocortical network hypersynchrony → spike-wave discharges (TISSUE). Extrasynaptic GABA-A activation in ventrobasal thalamocortical neurons deinactivates T-type Ca²⁺ currents and promotes burst firing, sustaining the ~3 Hz thalamo-cortico-thalamic oscillation. PMID:19966779: "the selective activation of thalamic extrasynaptic GABA(A) receptors is sufficient to elicit both electrographic and behavioral correlates of seizures in normal rats." Mouse counterpart: "The Slc6a+/A288V mouse, representative of MAE, had increased 5-7 Hz spike-wave discharges and absence seizures" (PMID:35840120); GAT-1^S295L/+ mice "have spike-and-wave discharges with motor arrest consistent with absence-type seizures" (PMID:37501613). UBERON: UBERON:0001897 dorsal plus ventral thalamus; UBERON:0001903 thalamic reticular nucleus; UBERON:0002596 ventral posterior nucleus of thalamus; UBERON:0001950 neocortex.

Node 6 — Developmental arm (TISSUE/ORGANISM). SLC6A1 is expressed in the developing brain very early — "abundantly expressed in the developing brain even before the CNS is formed" (PMID:34028503) — so GABAergic signaling is perturbed during circuit assembly, not just in the mature network. New evidence for an interneuron-development defect: human MGE organoids "uncover a previously unreported migration deficit of MGE interneurons in a disease model of SLC6A1 developmental and epileptic encephalopathy, offering potential insights into the developmental contributions to epileptogenesis" (PMID:40631166). GO: GO:0021853 cerebral cortex GABAergic interneuron migration; GO:0021894 cerebral cortex GABAergic interneuron development; GO:0007268 chemical synaptic transmission.

Node 7 — Clinical manifestation (ORGANISM). Epilepsy (absence, myoclonic-atonic, atonic, GTC), ID/language disorder, ASD, hypotonia, ataxia/tremor, behavioral dysregulation.

Cell types involved

Protein dysfunction and structure

GAT-1 is a LeuT-fold Na⁺/Cl⁻-coupled symporter. The full-length human GAT-1 cryo-EM structure with tiagabine (PMID:35676483) provides the structural frame used for variant interpretation: "Our structure reveals that tiagabine locks GAT1 in the inward-open conformation, by blocking the intracellular gate of the GABA release pathway, and thus suppresses neurotransmitter uptake." Machine-learning/homology modeling consistently predicts that pathogenic missense variants destabilize global protein conformation (PMID:35840120; PMID:31176687; PMID:33961861 — the last quantifying p.Val125Met at "~30% of the wildtype").

Metabolic, immune, and tissue-damage arms

• Metabolic: no primary metabolic defect. The ketogenic diet's efficacy (PMID:27600546) has prompted speculation about a diet–GABA-reuptake interaction, explicitly framed as a hypothesis: "An effect of the diet on gamma-aminobutyric acid reuptake mediated by gamma-aminobutyric acid transporter protein 1 is suggested."
• Immune system: not implicated. No autoimmune or inflammatory component.
• Tissue damage: no neurodegeneration, gliosis, or structural lesion is characteristic. Neuroimaging is typically normal. One outlier case describes a "Globus Pallidus Lesion With Iron Deposition and Dopaminergic Denervation" (PMID:38515990) — a single-case observation, not a disease feature.

Molecular profiling

• Transcriptomics: SLC6A1 longitudinal and cell-type-specific expression across human brain development was analyzed in PMID:33241211. Disease-specific patient transcriptomics: not available.
• Proteomics / metabolomics / lipidomics: not available for this disorder.
• Functional genomics: two scalable variant-effect platforms now exist — the ³H-GABA uptake MAVE-style survey of 213 variants (PMID:38781976) and a high-throughput GABA-fluorescence imaging assay (PMID:41279425). No CRISPR/RNAi modifier screen has been published.
• Single-cell / organoid: MGE organoid + cortical organoid fusion model (PMID:40631166); patient iPSC-derived astrocytes and neurons (PMID:34028503); a heterozygous G307R patient iPSC line, FINi007-A (PMID:41248596).

7. Anatomical Structures Affected

Organ level. Brain only (UBERON:0000955). Body system: nervous system. No primary involvement of other organ systems; GI symptoms (constipation/diarrhea) are common but are best modeled as secondary/comorbid rather than as primary organ involvement.

Regional. Thalamus (UBERON:0001897; thalamic reticular nucleus UBERON:0001903; ventrobasal complex UBERON:0002596) — the pacemaker of the spike-wave rhythm; cerebral cortex / neocortex (UBERON:0000956, UBERON:0001950); hippocampal formation (UBERON:0002421); cerebellar cortex (UBERON:0002129) — tremor/ataxia substrate, and the region where increased tonic conductance was first demonstrated. GAT-1 loss was confirmed in "cortex, hippocampus, thalamus and cerebellum" of both knock-in lines (PMID:38650830).

Tissue/cell level. Nervous tissue; GABAergic neurons and astrocytes (see table in §6). Note the transporter division of labor: GAT-3 (SLC6A11) "is only abundantly expressed in the thalamus and there was no compensatory increase of γ-aminobutyric acid transporter 3 in either of the mutant mouse lines" (PMID:38650830).

Subcellular level. Plasma membrane (GO:0005886) and presynaptic membrane (GO:0098793) — the normal destination; endoplasmic reticulum (GO:0005783) — the pathological destination; synapse (GO:0045202); Golgi apparatus (GO:0005794) — trafficking checkpoint.

Lateralization. Bilateral and generalized; there is no focal or lateralized anatomical signature. EEG abnormalities are generalized, with an occipital-predominant rhythmic delta component (OIRDA).

8. Temporal Development

Onset. Pediatric. Developmental concerns (language, hypotonia) in infancy/toddlerhood; epilepsy onset "typically between 14 months and 5 years" (PMID:42173049), mean 3.7 years in the Johannesen cohort. Onset pattern: insidious for the developmental phenotype, acute/episodic for seizures. Cognitive impairment precedes epilepsy in >60% of cases — clinically important because it argues the neurodevelopmental phenotype is not simply epileptic encephalopathy secondary to seizures.

Stages. No formal staging system exists. A pragmatic natural-history framing from the literature: 1. Infancy — hypotonia, feeding/motor mildness, emerging language delay; often no seizures. 2. Early childhood (1.5–5 y) — epilepsy onset (absence/myoclonic-atonic), EEG 2–4 Hz generalized spike-wave, possible regression episodes (mean 2.7 y). 3. Mid-childhood — seizure control achievable in many (20/31 became seizure-free, PMID:29315614), but cognition may deteriorate post-onset in ~46%. 4. Adolescence/adulthood — persistent ID (moderate-severe in 9/13 adults), refractory epilepsy in >60% of adults with epilepsy, ongoing behavioral/psychiatric burden; EEG rhythmic delta bursts "persisting from childhood to adulthood" (PMID:39889538).

Progression rate. Slow/variable; not a neurodegenerative course. Duration: chronic, lifelong.

Remission. Seizure remission is treatment-induced and common in childhood series (VPA-led); spontaneous remission is not documented. Cognitive/behavioral features do not remit.

Critical periods. Two, both actionable: - Regression window ~2–3 years, seizure/infection/spontaneously triggered (PMID:36895422). - Therapeutic window for gene replacement — the strongest preclinical efficacy signal is developmentally gated: "our data demonstrate compelling efficacy when mice are treated at an early development age" (PMID:39589822). Early diagnosis therefore has mechanistic, not merely administrative, value.

9. Inheritance and Population

Prevalence/incidence. GeneReviews: "Fewer than 500 individuals have been reported worldwide, with an estimated incidence of 2.65 in 100,000 births." Converted for dismech Prevalence structure: measure_type: BIRTH_PREVALENCE (best fit for an "incidence per births" statement), rate_per_100000: 2.65, prevalence_class: BAND_1_9_PER_100000. A second, cohort-based framing: pathogenic SLC6A1 variants account for ~4% of unsolved MAE (6/160; PMID:25865495) and a 1.7% diagnostic yield in 460 unselected epilepsy patients (PMID:30132828). Reported case count now exceeds 300 (PMID:39889538) and SLC6A1-NDD is described as "one of the most common monogenic disorders reported in genetic databases" (PMID:41066795) — the gap between reported cases and estimated birth incidence implies substantial under-ascertainment.

Inheritance pattern. Autosomal dominant, predominantly de novo. HP:0000006 Autosomal dominant inheritance.

Penetrance. Incomplete (GeneReviews). Rare inherited cases have parents with milder phenotypes (learning difficulties, epilepsy, behavior disorder) — the p.Ala334S hypomorph family being the best-characterized (PMID:41174879).

Expressivity. Highly variable, including intrafamilial variability (PMID:37502687; PMID:33961861).

Genetic anticipation. Not applicable — no repeat expansion.

Germline/gonadal mosaicism. Documented (PMID:33961861). GeneReviews recurrence-risk figure: ~1% when both parents test negative.

Founder effects. None reported. Recurrent variants arise independently at hypermutable CpG sites, not by descent (PMID:38781976).

Consanguinity. Not relevant (dominant, de novo).

Carrier frequency. Not applicable.

Population demographics. No ethnic or geographic predilection reported; cohorts are international (US, Europe, Korea, China, Turkey, India). Sex ratio: no established skew; note that male sex was associated with lower QOLCE-55 scores (PMID:41066795), an outcome rather than incidence finding. Age distribution: ascertained population is heavily pediatric; adults are "likely underrecognized due to limited genetic testing availability" (GeneReviews).

10. Diagnostics

Genetic testing (the definitive route)

Diagnosis requires a heterozygous pathogenic/likely pathogenic SLC6A1 variant plus a compatible phenotype (GeneReviews). Recommended approach: epilepsy multigene panel or comprehensive exome/genome sequencing, preferred over single-gene testing; sequence analysis detects >99% of pathogenic variants, del/dup analysis <1%.

• WES/WGS (MAXO:0009004 clinical whole-exome sequencing): first-line for unexplained DD/epilepsy; the route by which most cases have been found.
• Gene panels: any epilepsy/DEE or ID/ASD panel including SLC6A1.
• Chromosomal microarray: required to detect 3p25.3 microdeletions involving SLC6A1 ± SLC6A11 (PMID:25256099; PMID:39923323).
• Karyotype/FISH: low yield, but relevant for balanced translocations disrupting the locus (PMID:36966012; PMID:29621621) — consider when CMA is normal and there is a familial rearrangement.
• mtDNA testing, repeat expansion testing: not applicable.
• Variant interpretation aids: the SLC6A1 portal (https://slc6a1-portal.broadinstitute.org/) with structure-mapped pathogenicity (PMID:37647852); functional GABA-uptake data for 213 variants (PMID:38781976); high-throughput GABA-fluorescence assay for prospective VUS resolution (PMID:41279425); Drosophila allelic-series assay for hard VUS (PMID:41174879). Functional assay is the most useful VUS-resolution tool in this gene, given the 72% of ClinVar entries unscored.

Electrophysiology (MAXO:0000932 electroencephalography)

The disorder's most informative non-genetic test. GeneReviews: "2-4 Hz spike and wave discharges, exacerbated by hyperventilation, and intermittent rhythmic delta activity, especially in the occipital region." Johannesen: "irregular bursts of diffuse 2.5-3.5 Hz spikes/polyspikes-and-slow waves in 25/31"; two patients developed an ESES-like pattern. OIRDA is a recurring signature (PMID:33961861; PMID:39889538).

Emerging quantitative EEG biomarker (PMID:41893060): "Patients with SLC6A1-NDD exhibited significantly elevated delta power (19.4 ± 4.1) compared to controls (14.2 ± 3.0; p < 0.001)"; delta power increased with age in patients but declined in controls; wake-epoch classifier AUC = 0.93. Cross-platform concordance (EEGLAB vs Persyst) was imperfect (R² = 0.644) — the authors flag pipeline standardization as a prerequisite. This is the leading candidate objective endpoint for trials.

Laboratory tests and biomarkers

No diagnostic blood, urine, or CSF biomarker exists. No enzyme assay, no metabolite signature. Plasma/CSF GABA is not an established diagnostic test. This is a genuine gap: current biomarker development is entirely qEEG-based, with a possible future imaging biomarker — a GAT-1 PET tracer, [18F]GATT-44, is in first-in-human evaluation (NCT07457736, Yale, recruiting, start 2026-04), which would give direct target-engagement readout for chaperone and gene therapy trials.

Imaging

Brain MRI is typically normal; "No distinctive neuroimaging findings; nonspecific white matter changes possible" (GeneReviews). MRI's role is exclusionary.

Biopsy / pathology

Not applicable — no diagnostic histopathology.

Clinical criteria and differential diagnosis

No consensus diagnostic criteria for the gene-defined disorder; ILAE criteria for epilepsy with myoclonic-atonic seizures apply to the MAE subgroup (16/34 fulfilled MAE criteria in PMID:29315614). Differential (GeneReviews):

Screening

No newborn screening. No carrier screening (dominant, de novo). Cascade testing of parents is indicated for recurrence-risk counseling and to detect mildly affected/mosaic carriers.

11. Outcome / Prognosis

Survival/mortality. GeneReviews: "It is unknown whether life expectancy in individuals with SLC6A1-NDD is reduced." Survival into adulthood is documented. No published mortality rate, no SUDEP incidence estimate specific to this gene. Explicitly not available — an important gap to record rather than to fill by analogy.

Morbidity/disability. The dominant burden is lifelong intellectual and communication disability plus behavioral dysregulation, not seizure mortality. Adults: moderate-to-severe ID in 9/13; refractory epilepsy in 7/11 of those with epilepsy (PMID:37662110). Some individuals never develop verbal language despite better receptive communication (GeneReviews) — a strong argument for early AAC.

Quality-of-life measures. See §3. QOLCE-55 performed best as a disease-sensitive instrument; autism severity was the strongest cross-instrument driver (PMID:41066795; PMID:38663152).

Healthcare burden. Neurology is the most frequent specialty encounter; diagnosis reshapes rather than reduces utilization — "significant changes in types of HRU suggest that diagnosis leads to more appropriate care and treatment" (PMID:40624551).

Complications. Developmental regression episodes; status epilepticus including de novo absence status (PMID:37877664); ESES-like EEG evolution (PMID:29315614); injury from atonic drop attacks; sleep disruption; feeding/GI issues; caregiver/family strain.

Recovery potential. Skills lost in regression may or may not be recovered (PMID:36895422). Seizure freedom is attainable (20/31 in the childhood cohort) but does not reliably translate to cognitive gain: "There was no clear-cut correlation between seizure control and cognitive outcome" (PMID:29315614). This decoupling should be modeled explicitly — it is the central reason the field has moved to disease-modifying rather than purely anti-seizure therapy.

Prognostic factors. Residual GAT-1 uptake activity is the best-supported molecular prognostic marker (<10% residual → 4.6-fold enrichment for severe disease; PMID:37647852). Clinical prognostic markers: presence of regression, autism severity, absence seizures, coordination difficulty (all associated with lower QoL; PMID:41066795). Prognostic biomarkers: none validated; delta power is the leading candidate.

12. Treatment

Antiseizure pharmacotherapy

MAXO: MAXO:0000167 anticonvulsant agent therapy; NCIT:C15986 Pharmacotherapy for the generic action with therapeutic_agent bound to CHEBI (all CHEBI IDs below verified via OLS).

Dietary therapy

MAXO: MAXO:0030010 ketogenic diet intake (or MAXO:0000088 dietary intervention). Ketogenic diet supported by case-level response (PMID:27600546) and endorsed as an "evidence-supported adjunctive option" (PMID:42173049); low glycemic index therapy reported in drug-refractory SLC6A1 MAE (PMID:38443714).

Disease-modifying: pharmacological chaperone (4-phenylbutyrate)

The most advanced repurposing program. Rationale: restore trafficking of ER-retained mutant and wild-type GAT-1, exploiting the fact that every patient retains one normal allele.

• Preclinical: "4-Phenylbutyrate increased γ-amino butyric acid uptake in both mouse and human astrocytes and neurons bearing the variants… 4-phenylbutyrate alone increased γ-amino butyric acid transporter 1 expression and suppressed spike wave discharges in heterozygous knockin mice" (PMID:35911425).
• Mechanism resolved: "PBA restored GABA uptake and GAT-1 surface expression across all variants, and TUDCA mimicked the effects of PBA. HDAC inhibitors exhibited modest rescue in vitro but failed to restore GAT-1 function or mitigate seizures in the knockin mice… PBA acts as a pharmacochaperone, not an HDAC inhibitor" (PMID:42157447). TUDCA (CHEBI:80774) is therefore a rational second chaperone candidate.
• Beyond seizures: PBA improved motor and sleep phenotypes in Slc6a1^+/S295L mice, "supporting its potential as a disease-modifying therapy" (PMID:41385967).
• Clinical: Phase Early-1 NCT04937062 (glycerol phenylbutyrate / Ravicti; Weill Cornell; STXBP1 + SLC6A1 DEE; active, not recruiting). Scoping review summary: "4-phenylbutyrate restores GAT-1 trafficking in endoplasmic reticulum-retained variants and has demonstrated seizure reduction in 80% and seizure freedom in 40% of treated patients in the largest clinical cohort" (PMID:42173049).
• Real-world safety/efficacy (PMID:42447769, n=18 STXBP1+SLC6A1): "Among 11 children with uncontrolled seizures, 8 showed improvement (all with ≥50% seizure reduction), resulting in a 73% seizure response rate. Nearly all families (17/18) reported improvements in development." Toxicity: mild (sedation, decreased appetite, nausea) in 14/18, resolving in 2–10 days; one severe event — "metabolic acidosis and aspiration pneumonia requiring intubation."
• 3p25.3 deletion patients also showed benefit: "Post-treatment EEGs showed a moderate reduction in epileptiform discharges following PBA administration, and patients exhibited improved motor function" (PMID:39923323).

CHEBI: CHEBI:41500 4-phenylbutyric acid; CHEBI:134745 glycerol phenylbutyrate. Therapeutic modality: SMALL_MOLECULE.

Disease-modifying: gene replacement therapy

MAXO: MAXO:0001001 gene therapy. Modality: GENE_THERAPY.

• Preclinical (PMID:39589822): AAV9 vectors with JeT or MeP promoters. "Neonatal intracerebroventricular administration of either vector resulted in significantly normalized EEG patterns in Slc6a1-/- or Slc6a1+/- mice as well as improvement in several behavioral phenotypes." Critically: "our treatments in the heterozygous mice, which genotypically match human patients, have resulted in stronger benefits," while neonatal treatment carried "some mortality and adverse effects."
• Clinical: NCT07173153, "Gene Therapy for SLC6A1 Neurodevelopmental Disorder," AAV9.SLC6A1, Phase 1/2, enrolling by invitation, start 2025-08-25, sponsor Emily de los Reyes (Nationwide Children's). First patient dosed December 2025 (PMID:42173049).
• Combination strategy in preprint: 4-PBA plus gene augmentation as dual therapy (PMID:42327277) — preprint, not peer-reviewed; flag accordingly.

Other advanced modalities

• RNA-based therapies (ASO, siRNA): none in development for SLC6A1. Note the mechanistic mismatch — haploinsufficiency calls for allele upregulation, so a TANGO-style splice-modulating or upregulating ASO would be the theoretically apt design, but none is published. AJHG 2024 frames the therapeutic goal precisely: "Strategies to increase the expression of the wild-type SLC6A1 allele are likely to be beneficial across neurodevelopmental disorders" (PMID:38781976).
• Cell therapy, immunotherapy, targeted oncology-style therapy: not applicable.
• Surgery: no role. Epilepsy is generalized; resective surgery is not indicated. VNS/corpus callosotomy for drop attacks would follow generic refractory-generalized-epilepsy practice — no SLC6A1-specific evidence.

Supportive, rehabilitative, and behavioral care

Per GeneReviews (MAXO terms in brackets): speech-language therapy with early consideration of AAC devices [MAXO:0000930 speech therapy]; physical therapy [MAXO:0000011]; occupational therapy [MAXO:0001351]; developmental/educational support [MAXO:0009101 early intervention services]; gastroenterology evaluation for GI dysfunction; multidisciplinary coordination and family/social-work support [MAXO:0000950 supportive care].

Behavioral/psychiatric pharmacotherapy: stimulants for ADHD; risperidone or aripiprazole (FDA-approved for irritability in ASD) for irritability/aggression; sleep hygiene plus melatonin, clonidine, or trazodone for sleep disturbance (GeneReviews).

Pharmacogenomics

No CPIC/PharmGKB guideline specific to SLC6A1. The relevant "pharmacogenomic" logic is genotype-mechanism-guided rather than metabolism-guided: chaperone therapy is predicted to benefit trafficking-defective/ER-retained variants (about two-thirds of LoF missense) more than surface-expressed-but-inactive variants (the remaining third) (PMID:38781976). Curate as a personalized-medicine hypothesis, not established practice.

Treatment algorithm (synthesized)

1. Confirm genetic diagnosis → 2. First-line valproate; add lamotrigine and/or ethosuximide by seizure type; clobazam as adjunct → 3. Monitor for levetiracetam behavioral intolerance; avoid GAT-1 inhibitors → 4. If drug-resistant: ketogenic diet or low glycemic index therapy; consider adjunctive acetazolamide → 5. Concurrently and from diagnosis: speech/AAC, PT/OT, behavioral and sleep management → 6. Consider trial enrollment (phenylbutyrate, AAV9 gene therapy, natural history) — noting the developmentally gated therapeutic window.

13. Prevention

Primary prevention. Not possible for de novo dominant disease. No vaccination, exposure modification, or population-level intervention applies.

Secondary prevention (early detection). The dominant actionable lever. Early genetic testing is explicitly recommended: PMID:39889538 concludes the electroclinical/neurodevelopmental profile "suggest[s] the importance of early genetic testing for SLC6A1-NDD diagnosis." Because gene-therapy efficacy is developmentally gated (PMID:39589822) and cognitive impairment precedes epilepsy in >60% (PMID:42173049), shortening time-to-diagnosis has direct therapeutic consequence — the HRU study makes the same argument from the health-systems side: stakeholders "should consider the value of an early diagnosis to improve long-term outcomes" (PMID:40624551). No newborn screening program includes SLC6A1.

Tertiary prevention. Seizure control to reduce regression risk (seizures are a documented regression trigger, PMID:36895422); avoidance of behaviorally destabilizing and mechanistically counterproductive drugs; injury prevention for atonic drop attacks (protective headgear); sleep and behavioral management; surveillance of development, seizures, movement disorder, and GI symptoms at each visit (GeneReviews).

Genetic counseling. MAXO:MAXO:0000079 genetic counseling. 50% transmission risk from an affected individual; ~1% empiric recurrence risk to siblings when both parents test negative, due to possible parental gonadal mosaicism — a risk that is not theoretical here (PMID:33961861). Prenatal and preimplantation genetic testing are available once the familial variant is known (GeneReviews).

Immunization, public health, environmental interventions, prophylaxis. Not applicable.

14. Other Species / Natural Disease

Taxonomy and orthologs (NCBI Gene IDs retrieved via eSearch):

Naturally occurring disease in other species. None reported. No OMIA entry for a naturally occurring SLC6A1 disorder in companion animals or livestock; no wildlife disease. All animal disease is experimentally induced.

Breed-specific disease (VBO). Not applicable — no breed predisposition described.

Comparative biology. GAT-1 is deeply conserved across bilaterians; the SLC6/NSS fold is conserved back to bacterial LeuT, which is precisely why LeuT-based homology models were used for variant interpretation before the human cryo-EM structure existed (PMID:35676483). The disease mechanism is functionally conserved: mouse KO reproduces tremor, ataxia, and increased cerebellar tonic conductance (PMID:15788781); Drosophila expressing patient variants "confirm phenotypes in flies… consistent with a partial loss-of-function mechanism" (PMID:41174879). This cross-phylum reproducibility is the strongest argument that the primary lesion is transporter function per se, not a human-specific interaction.

Zoonotic potential / cross-species transmission. Not applicable — genetic disorder.

15. Model Organisms

Mouse (primary system)

Key modeling insight for KB curation: the homozygous null is the worse model for translation. PMID:39589822: "the severe homozygous KO model is more refractory to treatment, whereas our treatments in the heterozygous mice, which genotypically match human patients, have resulted in stronger benefits." Curate mouse-derived efficacy claims with evidence_source: MODEL_ORGANISM and note zygosity.

Model limitations. Mice do not model language, autism, or intellectual disability in any construct-valid way — precisely the domains that dominate patient QoL. Absence-type SWDs and motor phenotypes are well captured; the neurodevelopmental core is not. This is a legitimate HUMAN_MODEL_MISMATCH discussion candidate for the dismech entry.

Human cellular and organoid systems

• Patient iPSC-derived astrocytes and neurons — showed that "the loss of GABA uptake function and endoplasmic reticulum retention is consistent across induced pluripotent stem cell-derived cell types, including astrocytes and neurons" (PMID:34028503). Deposited line: FINi007-A, heterozygous G307R (PMID:41248596).
• MGE organoids fused to cortical organoids — revealed an interneuron migration deficit in an SLC6A1 DEE model (PMID:40631166). Preprint; verify on peer-reviewed publication before curating as established.
• HEK293T / HeLa heterologous expression with ³H-GABA uptake and surface biotinylation — the workhorse assay across the variant-function literature (PMID:30132828; PMID:31176687; PMID:33961861; PMID:38781976).
• High-throughput GABA-fluorescence imaging assay for scalable variant classification (PMID:41279425; preprint).

Invertebrate

Drosophila melanogaster allelic series expressing patient SLC6A1 variants, used to resolve a VUS (p.Ala334S) as a hypomorph (PMID:41174879).

Databases and resources

MGI (mouse Slc6a1), RGD (rat), ZFIN (zebrafish slc6a1a/b), FlyBase, Alliance of Genome Resources, IMSR/KOMP for allele availability, Cellosaurus/hPSCreg for FINi007-A, and the disease-specific SLC6A1 portal (Broad) for variant-level function.

Curation notes for the dismech entry

1. Ontology gap to flag: MONDO lacks a gene-defined "SLC6A1-related neurodevelopmental disorder" class; MONDO:0014633 is seizure-syndrome-scoped and already used by Epilepsy_with_Myoclonic_Atonic_Seizures.yaml. Consider a MONDO term request and, meanwhile, an explicit notes statement plus differentials linking the two entries.
2. Module conformance candidates: epilepsy_excitation_inhibition_imbalance (conform at #Excitation-Inhibition Imbalance, but with an inverted sign — this disorder produces excess tonic inhibition in thalamus, an instructive edge case worth a mechanistic_hypotheses note rather than a silent conformance). Also consider a trafficking/ER-retention pattern — this disorder shares the misfolding→ER-retention→degradation→pharmacochaperone-rescue chain with CFTR/ΔF508 (explicitly drawn as an analogy in PMID:35911425), which may warrant a new "misfolded membrane protein ER retention" module if other dismech entries share it.
3. Competing-mechanism curation: dominant-negative oligomerization (PMID:35911425, in vitro) vs pure haploinsufficiency (PMID:38781976, 213-variant scale). Use hypothesis_groups on the relevant causal edges; the large-scale functional data currently favors haploinsufficiency.
4. Evidence-source discipline: the therapeutic literature is heavily MODEL_ORGANISM and IN_VITRO. Only PMID:41131961 (acetazolamide, n=6), PMID:42447769 (PBA parent-report, n=18), PMID:29315614 / PMID:37662110 (ASM effectiveness in cohorts) are HUMAN_CLINICAL, and none is randomized. The scoping review explicitly names this: "Critical gaps include the absence of prospective natural history data with standardized outcomes, lack of randomized controlled trials, and incomplete characterization of the adult phenotype" (PMID:42173049).
5. Preprints to hold: PMID:42327277, PMID:41648160, PMID:41279425, PMID:40631166, PMID:39399018 are bioRxiv/medRxiv. Note that PMID:39399018 (medRxiv) and PMID:41174879 (HGG Adv) are the same work — cite the journal version.
6. Clinical trials to include: NCT07173153 (AAV9 gene therapy, Ph1/2), NCT04937062 (glycerol phenylbutyrate, Early Ph1), NCT07531511 (UCB prospective natural history), NCT01238250 (Simons Searchlight registry), NCT07457736 ([18F]GATT-44 GAT-1 PET, healthy volunteers — relevant as a future biomarker, not a treatment).

Sources

• SLC6A1-Related Neurodevelopmental Disorder — GeneReviews (NCBI Bookshelf)
• SLC6A1–Related Neurodevelopmental Disorder: A Scoping Review — Pediatr Neurol 2026 (PMID:42173049)
• Current knowledge of SLC6A1-related neurodevelopmental disorders — Brain Commun 2020 (PMID:33241211)
• Common molecular mechanisms of SLC6A1 variant-mediated NDDs in astrocytes and neurons — Brain 2021 (PMID:34028503)
• AAV9/SLC6A1 gene therapy rescues abnormal EEG patterns — J Clin Invest 2024 (PMID:39589822)
• The phenotypic presentation of adult individuals with SLC6A1-related NDDs — Front Neurosci 2023 (PMID:37662110)
• Phenotypic similarities and differences between SLC6A1-NDD and GLUT1 deficiency — Seizure 2025 (PMID:40311539)
• AAV9.SLC6A1 Gene Therapy in SLC6A1 — NCT07173153
• SLC6A1-related Neurodevelopmental Disorder — NORD
• PubMed/NCBI E-utilities (abstracts, ClinVar counts, Gene IDs), ClinicalTrials.gov API v2, gnomAD GraphQL API, EMBL-EBI OLS4 API, UniProt REST — all queried 2026-07-25.